Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + Oxaliplatin + TAS-102 in First-line Advanced Colorectal Cancer
NCT05364489Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jun 2022
- Primary completion
- Jun 2025
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of trifluridine + tipiracil in colorectal cancer (CRC), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Progression Free Survival up to 24 months. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
trifluridine + tipiracil
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05364489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05364489.